Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
IRVINE, Calif., Aug. 23, 2017 -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Foundation Medicine, Inc. (“Foundation” or the “Company”) (Nasdaq:FMI). Investors who purchased or otherwise acquired Foundation shares from February 26, 2014 through November 3, 2015, inclusive (the “Class Period”), are encouraged to contact the Firm before the September 26, 2017 lead plaintiff motion deadline.
If you purchased Foundation shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.
According to the Complaint, throughout the Class Period, Foundation made false and/or misleading statements, and/or failed to disclose, material information to investors. On July 29, 2015, the Company announced that it was not making the strides obtaining coverage it claimed to have been making during the Class Period, and that Foundation would receive no Medicare payments in 2015 for its tumor profiling tests due to a delay in receiving a local coverage determination from its regional Medicare Administrative Contractor. As a result of the delay, the Company cut its 2015 financial guidance, which was based on an assumption that Medicare approval was going to be obtained in 2015. On this news, Foundation’s stock price fell significantly. On November 3, 2015, the Company revealed another revision to the already reduced number of clinical tests it expected to report for 2015. When this news reached the public, shares of Foundation declined in value materially, which caused investors harm according to the Complaint.
If you wish to learn more about this lawsuit, or if you have any questions about this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or by e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
